AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir
1/29/2013 10:55:50 AM
More...
|
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact
10/30/2012 1:02:13 PM
More...
|
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in Preparation for Phase III
8/7/2012 10:39:46 AM
More...
|
Results of AiCuris's Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants Meeting Both Primary Efficacy Endpoints to be Presented at International Conferences
4/2/2012 9:50:12 AM
More...
|
AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients
2/14/2012 9:50:00 AM
More...
|
AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA
1/5/2012 9:32:17 AM
More...
|
AiCuris: No Resistant Herpes Simplex Virus (HSV) Observed in Phase II Trial with Herpes Drug AIC316
9/6/2011 11:15:58 AM
More...
|
AiCuris' HCMV Drug Letermovir (AIC246) Receives Fast Track from FDA, New Data to be Presented at 51st ICAAC
8/29/2011 9:08:41 AM
More...
|
AiCuris' Novel HSV Compound AIC316 Shows Efficacy in Phase II
7/18/2011 9:34:36 AM
More...
|
AiCuris Receives Orphan Drug Designation for its Innovative Phase II Drug AIC246 for the Prevention of HCMV Disease
4/21/2011 10:15:55 AM
More...
|
|